Form 4: Artiva Biotherapeutics: 5AM Partners VI, LLC Reports Beneficial Ownership Changes Following IPO

5AM Partners VI, LLC and related entities report changes in beneficial ownership of Artiva Biotherapeutics (ARTV) common stock following the company's initial public offering (IPO).

Summary

• 5AM Partners VI, LLC, along with affiliated entities and individuals, filed a Form 4 detailing changes in beneficial ownership of Artiva Biotherapeutics, Inc. (ARTV) common stock.
• The filing reflects transactions occurring on July 22, 2024, primarily related to the conversion of preferred stock and simple agreements for future equity (SAFE) into common stock upon the closing of Artiva's IPO.
• Series A and Series B Preferred Stock converted into common stock on a one-for-one basis.
• Outstanding SAFEs converted into common stock at a 15% discount to the IPO price, with $1,152,253.93 converting into 112,966 shares and $3,556,957.78 converting into 348,721 shares.
• The reporting entities include 5AM Ventures VI, L.P., 5AM Opportunities II, L.P., and their respective general partners, as well as individuals Kush Parmar and Andrew J. Schwab, who may be deemed to have shared voting and investment power over the shares.
• After the reported transactions, 5AM Ventures VI, L.P. beneficially owns 1,171,250 shares of common stock, and 5AM Opportunities II, L.P. beneficially owns 1,182,054 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The filing reflects standard post-IPO transactions and continued significant ownership by key investors, suggesting confidence in the company's future.

Positives

• The conversion of preferred stock and SAFEs into common stock simplifies Artiva's capital structure following the IPO.
• The filing indicates continued significant ownership by 5AM Ventures and related entities, suggesting ongoing confidence in the company.

Industry Context

Form 4 filings are standard practice after an IPO, providing transparency into the ownership structure of the newly public company. The conversion of preferred stock and SAFEs is a typical event following an IPO, as these instruments are often designed to convert into common stock upon the company going public.

Comparison to Industry Standards

• The conversion of preferred stock to common stock upon an IPO is a standard practice in the biotechnology industry, similar to companies like CRISPR Therapeutics and Iovance Biotherapeutics.
• The 15% discount on SAFE conversions is within the typical range observed in early-stage biotech financing, comparable to deals seen with companies like Graphite Bio prior to their IPO.

Stakeholder Impact

• Shareholders: The conversion of preferred stock and SAFEs into common stock dilutes existing shareholders to a small degree.
• Employees: No direct impact on employees is apparent from this filing.

Key Dates